Cargando…

Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies

Background: The usefulness of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) for the assessment of idiopathic inflammatory myopathies (IIMs) is acknowledged, but laboratory standardization remains a challenge. We detected MSAs/MAAs by multi-analytic line immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghirardello, Anna, Gatto, Mariele, Franco, Chiara, Zanatta, Elisabetta, Padoan, Roberto, Ienna, Luana, Gallo, Nicoletta, Zen, Margherita, Lundberg, Ingrid E., Mahler, Michael, Doria, Andrea, Iaccarino, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572214/
https://www.ncbi.nlm.nih.gov/pubmed/37835823
http://dx.doi.org/10.3390/diagnostics13193080
_version_ 1785120182547513344
author Ghirardello, Anna
Gatto, Mariele
Franco, Chiara
Zanatta, Elisabetta
Padoan, Roberto
Ienna, Luana
Gallo, Nicoletta
Zen, Margherita
Lundberg, Ingrid E.
Mahler, Michael
Doria, Andrea
Iaccarino, Luca
author_facet Ghirardello, Anna
Gatto, Mariele
Franco, Chiara
Zanatta, Elisabetta
Padoan, Roberto
Ienna, Luana
Gallo, Nicoletta
Zen, Margherita
Lundberg, Ingrid E.
Mahler, Michael
Doria, Andrea
Iaccarino, Luca
author_sort Ghirardello, Anna
collection PubMed
description Background: The usefulness of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) for the assessment of idiopathic inflammatory myopathies (IIMs) is acknowledged, but laboratory standardization remains a challenge. We detected MSAs/MAAs by multi-analytic line immunoassay (LIA) and particle-based multi-analyte technology (PMAT) in a multicenter cohort of patients with IIMs. Methods: We tested the sera from 411 patients affected with definite IIM, including 142 polymyositis (PM), 147 dermatomyositis (DM), 19 cancer-associated myositis, and 103 overlap myositis syndrome (OM), and from 269 controls. MSAs/MAAs were determined by 16Ags LIA in all sera, and anti-HMGCR by ELISA in 157/411 IIM sera and 91/269 control sera. The analytical specificity of LIA/HMGCR ELISA was compared with that of PMAT in 89 MSA+ IIM sera. Results: MSAs/MAAs were positive in 307/411 (75%) IIM patients and 65/269 (24%) controls by LIA (Odds Ratio 9.26, 95% CI 6.43–13.13, p < 0.0001). The sensitivity/specificity of individual MSAs/MAAs were: 20%/100% (Jo-1), 3%/99.3% (PL-7), 4%/98.8% (PL-12), 1%/100% (EJ), 0.7%/100% (OJ), 9%/98% (SRP), 5.6%/99.6% (TIF1γ), 4.6%/99.6% (MDA5), 8%/96% (Mi-2), 1.5%/98% (NXP2), 1.7%/100% (SAE1), 4%/92% (Ku), 8.5%/99% (PM/Scl-100), 8%/96% (PM/Scl-75), and 25.5%/79% (Ro52). Anti-HMGCR was found in 8/157 (5%) IIM patients and 0/176 (0%) controls by ELISA (p = 0.007). Concordance between LIA/HMGCR ELISA and PMAT was found in 78/89 (88%) samples. Individual MSAs detected by LIA were associated with IIM subsets: Jo-1 with PM and OM, PL-12 with OM, Mi-2, TIF1γ, and MDA5 with DM, SRP with PM, and PM/Scl-75/100 with OM (p < 0.001 for all). Conclusions: Since MSAs are mostly mutually exclusive, multi-specific antibody profiling seems effective for a targeted clinical-serologic approach to the diagnosis of IIMs.
format Online
Article
Text
id pubmed-10572214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105722142023-10-14 Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies Ghirardello, Anna Gatto, Mariele Franco, Chiara Zanatta, Elisabetta Padoan, Roberto Ienna, Luana Gallo, Nicoletta Zen, Margherita Lundberg, Ingrid E. Mahler, Michael Doria, Andrea Iaccarino, Luca Diagnostics (Basel) Article Background: The usefulness of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) for the assessment of idiopathic inflammatory myopathies (IIMs) is acknowledged, but laboratory standardization remains a challenge. We detected MSAs/MAAs by multi-analytic line immunoassay (LIA) and particle-based multi-analyte technology (PMAT) in a multicenter cohort of patients with IIMs. Methods: We tested the sera from 411 patients affected with definite IIM, including 142 polymyositis (PM), 147 dermatomyositis (DM), 19 cancer-associated myositis, and 103 overlap myositis syndrome (OM), and from 269 controls. MSAs/MAAs were determined by 16Ags LIA in all sera, and anti-HMGCR by ELISA in 157/411 IIM sera and 91/269 control sera. The analytical specificity of LIA/HMGCR ELISA was compared with that of PMAT in 89 MSA+ IIM sera. Results: MSAs/MAAs were positive in 307/411 (75%) IIM patients and 65/269 (24%) controls by LIA (Odds Ratio 9.26, 95% CI 6.43–13.13, p < 0.0001). The sensitivity/specificity of individual MSAs/MAAs were: 20%/100% (Jo-1), 3%/99.3% (PL-7), 4%/98.8% (PL-12), 1%/100% (EJ), 0.7%/100% (OJ), 9%/98% (SRP), 5.6%/99.6% (TIF1γ), 4.6%/99.6% (MDA5), 8%/96% (Mi-2), 1.5%/98% (NXP2), 1.7%/100% (SAE1), 4%/92% (Ku), 8.5%/99% (PM/Scl-100), 8%/96% (PM/Scl-75), and 25.5%/79% (Ro52). Anti-HMGCR was found in 8/157 (5%) IIM patients and 0/176 (0%) controls by ELISA (p = 0.007). Concordance between LIA/HMGCR ELISA and PMAT was found in 78/89 (88%) samples. Individual MSAs detected by LIA were associated with IIM subsets: Jo-1 with PM and OM, PL-12 with OM, Mi-2, TIF1γ, and MDA5 with DM, SRP with PM, and PM/Scl-75/100 with OM (p < 0.001 for all). Conclusions: Since MSAs are mostly mutually exclusive, multi-specific antibody profiling seems effective for a targeted clinical-serologic approach to the diagnosis of IIMs. MDPI 2023-09-28 /pmc/articles/PMC10572214/ /pubmed/37835823 http://dx.doi.org/10.3390/diagnostics13193080 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ghirardello, Anna
Gatto, Mariele
Franco, Chiara
Zanatta, Elisabetta
Padoan, Roberto
Ienna, Luana
Gallo, Nicoletta
Zen, Margherita
Lundberg, Ingrid E.
Mahler, Michael
Doria, Andrea
Iaccarino, Luca
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
title Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
title_full Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
title_fullStr Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
title_full_unstemmed Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
title_short Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
title_sort detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572214/
https://www.ncbi.nlm.nih.gov/pubmed/37835823
http://dx.doi.org/10.3390/diagnostics13193080
work_keys_str_mv AT ghirardelloanna detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT gattomariele detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT francochiara detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT zanattaelisabetta detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT padoanroberto detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT iennaluana detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT gallonicoletta detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT zenmargherita detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT lundbergingride detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT mahlermichael detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT doriaandrea detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies
AT iaccarinoluca detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies